Company intelligence / Profile preview

Spear Bio

Woburn, Massachusetts, United Statesspear.bio ↗

Ownership: Private
Development stage: Commercial

Overview

Spear Bio has developed an ultra-sensitive immunoassay platform capable of detecting protein biomarkers at attomolar concentrations from sub-microliter samples. Their lead diagnostic program—a blood test for pTau217—has received FDA Breakthrough Device Designation and targets early detection of Alzheimer’s disease. The company raised $45M in Series A financing in July 2025 to accelerate product launch and commercialization efforts.

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Immunoassay platform (Successive Proximity Extension Amplification Reaction)Diagnostic test (not a therapeutic modality but relevant for context)
Industry: Protein Biomarker Diagnostics

Partnerships

Foresite Capital (investor with board representation)Bio-Techne (strategic investor)

Beyond the preview

Go deeper on Spear Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spear Bio.

Explore the full profile